铁治疗对慢性心力衰竭和缺铁性贫血的影响:系统性审查和元分析
Yusra Pintaningrum1, Ni Putu Yunandari2
1Cardiology and Vascular Department, Faculty of Medicine and Health Science, Mataram University, Mataram, Indonesia. yusra@unram.ac.id.
概括
静脉注射铁疗法显著改善慢性心力衰竭和缺铁性贫血患者的功能能力. 这种治疗还可以将住院风险降低55%,并降低死亡风险.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与缺铁 (ID) 相关的心力衰竭 (HF) 与功能减弱,生活质量差以及住院和死亡率增加有关.
- 缺铁性贫血 (IDA) 是慢性心力衰竭 (CHF) 患者常见的并发症.
研究的目的:
- 系统地审查和分析口服和静脉注射铁疗法的影响功能能力,住院和死亡率在CHF患者与IDA.
主要方法:
- 在过去20年发表的研究中,使用PRISMA指南在Cochrane图书馆,PubMed Central和Medline数据库中进行系统的文献搜索.
- 使用RevMan版本5.4对选定的科学文章进行的元分析.
主要成果:
- 静脉注射铁疗法在6分钟步行测试 (6MWT) 中显著改善30.82米.
- 与安慰剂相比,接受静脉注射铁的患者住院风险降低了55% (RR=0.45) 和死亡风险降低 (RR=0.18).
- 这些改善在统计学上是显著的,表明IV铁在CHF患者具有IDA的整体积极效果.
结论:
- 静脉注射铁疗法有效改善慢性心力衰竭和缺铁性贫血患者的功能能力.
- 这种疗法显著降低了该患者群体的住院风险55%和死亡率.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352


